Sam Altman AI regulation stance favors broad access
OpenAI’s Sam Altman set out how his AI regulation views diverge from Anthropic, backing broad access to the technology while supporting tougher safeguards in some areas.
FDA peptides advisory could widen access to unapproved drugs
An FDA advisory supports allowing six unapproved peptide products through compounding pharmacies, prompting debate over safety, evidence and oversight.